In the ACE-CL-001 trial, data showed 97% of previously untreated CLL patients continued to respond to treatment after more than four years with no new safety signals.
In the pivotal ASCEND trial, an estimated 82% of CLL patients with relapsed or refractory disease treated with Calquence remained progression free at 18 months vs. 48% for comparators. Overall, Calquence data delivered meaningful long-term clinical benefit with a favorable safety profile for patients with CLL, regardless of whether they’re new to treatment or are managing relapsed or refractory disease.
A link to the ACE-CL-001 trial abstract can be found here, and the ASCEND trial abstract here.
